Bio-Rad Laboratories has expanded its StarBright fluorescent dye portfolio with the introduction of StarBright UltraViolet700 (SBUV700), specifically engineered for spectral flow cytometry applications in immunology research. The new dye represents the first in a planned series rollout over the coming months, targeting enhanced panel design capabilities for clinical laboratories and research institutions.
TRIMERO Diagnostics offers IVD CE marked assays for testing Soluble Transferrin Receptor (sTfR).
DiaSys | Reliable and innovative since 1991
High-performance analyses with minimal hands-on time
Excellence in Science
The on-demand solution that saves more than time.
Researchers have developed CRISPR-GPT,an artificial intelligence system that can autonomously design and guide complete gene-editing experiments from start to finish. The multi-agent platform successfully orchestrated knockout experiments and epigenetic activation in human cell lines, marking a significant step towards AI-driven biological research automation.
Laboratory leaders worldwide are embracing digital pathology and artificial intelligence as essential tools to address mounting staffing shortages and financial pressures whilst advancing precision medicine initiatives. A comprehensive survey of 360 senior professionals reveals overwhelming confidence in AI-driven pathology’s readiness for clinical implementation.
Newcastle-based Leica Biosystems has launched ChromoPlex III Triple Detection RUO, a chromogenic multiplex immunohistochemistry detection system designed to simplify assay workflows whilst enhancing reproducibility for digital pathology applications. The research-use-only system addresses growing demand for accessible multiplex IHC tools in spatial biology research and tumour microenvironment characterisation.
Revvity has launched pHSense™ reagents, a breakthrough technology designed to advance internalization studies in drug discovery workflows. The innovative system targets researchers investigating G protein-coupled receptors (GPCRs) and antibody-drug conjugates (ADCs), offering enhanced accuracy and scalability for therapeutic development programmes.
March 2026
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.